Wednesday, July 8, 2026

Patent intelligence · US

US 12421269

SGLT2/DPP4 inhibitor and application thereof

granted A61PA61P3/10
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 335
Patent details — US 12421269

Quick answer

US 12421269 (SGLT2/DPP4 inhibitor and application thereof) is held by CGeneTech (Suzhou, China) CO., Ltd.. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
9
CPC classes
A61P, A61P3/10

More from CGeneTech (Suzhou, China) CO., Ltd.

Related pharmaceutical patents in our USPTO index.

  1. US 12427137

    Method for reducing methane production in animal stomach

    China Agricultural University · Expires Sep 25, 2045

    granted
  2. US 12403167

    Phenylethanoid glycoside extract from Acanthus ilicifolius L., preparation method thereof and use as anti-liver injury medicament

    OCEAN UNIVERSITY OF CHINA · Expires Aug 28, 2045

    granted
  3. US 12397034

    Pharmaceutical composition for promoting neurogenesis and method for promoting neurogenesis and inhibiting senescence of brain neurons

    China Medical University · Expires Aug 21, 2045

    granted
  4. US 12389931

    Oyster peptide with effect of improving sexual function and preparation method thereof

    CHINA NATIONAL RESEARCH INSTITUTE OF FOOD & FERMENTATION INDUSTRIES CO., LTD. · Expires Aug 14, 2045

    granted
  5. US 12383535

    Hydrogen peroxide-responsive KEAP1-NRF2 ppi inhibitor prodrug, and preparation method therefor

    CHINA PHARMACEUTICAL UNIVERSITY · Expires Aug 7, 2045

    granted
  6. US 12378241

    Pyridine derivative as FGFR and VEGFR dual inhibitors

    CGeneTech (Suzhou, China) CO., Ltd. · Expires Jul 31, 2045

    granted
  7. US 12371434

    MLL1 inhibitors and anti-cancer agents

    CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. · Expires Jul 24, 2045

    granted

Frequently asked questions

What is US patent 12421269?

US 12421269 (SGLT2/DPP4 inhibitor and application thereof) is held by CGeneTech (Suzhou, China) CO., Ltd.. Status: granted. Granted Sep 23, 2025. Expires Sep 18, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12421269?

CGeneTech (Suzhou, China) CO., Ltd. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 335 pharmaceutical patents for this assignee.

When does US 12421269 expire?

Our index shows an expiration date of Sep 18, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.